A phase 1, single- center, randomized, partially- blind, PBO- controlled, 1 arm study assessing the effect of co-administration of Zavegepant plus sumatriptan on resting blood pressure (BP) in healthy participants
Latest Information Update: 14 Jun 2023
At a glance
- Drugs Sumatriptan (Primary) ; Zavegepant (Primary)
- Indications Allergic asthma; COVID-19 respiratory infection; Migraine
- Focus Pharmacodynamics
Most Recent Events
- 27 Apr 2023 Results assessing the effect of zavegepant and concomitant sumatriptan on blood pressure and pharmacokinetics in healthy adult participants, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 05 Aug 2022 New trial record
- 12 Jun 2022 Results presented at the 64th Annual Scientific Meeting of the American Headache Society